NCT04119687 - Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2026

Conditions

Osteoarthritis, Knee

Interventions

BIOLOGICAL

FX201

FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.

Trial Locations (6)

16602

University Orthopedics Center, Altoona

16635

Altoona Center for Clinical Research, Duncansville

34232

Gulfcoast Research Institute, LLC, Sarasota

64114

Center for Pharmaceutical Research, Kansas City

75231

Metroplex Clinical Research Center, Dallas

85053

Arizona Research Center, Phoenix